yellow-brown powders from the mycelia of a soil actinomycete, Streptomyces sp. WK-3419. Their physico-chemical properties showed that they are chlorinated peptides. Chloropeptin I (C61H45N7O15C16) is a novel compound, but chloropeptin II was identified as complestatin. Both compounds inhibited gpl20-CD4 binding (IC50: 1.3 and 2.0 /xm, respectively), the cytopathic effect of HIV in MT-4 cells (EC50: 1.6 and 1.7^M, respectively) and syncytium formation in co-cultured HIV-1-infected and uninfected MOLT-4 cells (IC50: 0.5 and 1.1^m, respectively).
Chloropeptin I was synergistic in the inhibition of the cytopathic effect whencombined with other anti-HIV drugs such as zidovudine (AZT), didanosine (ddl), zalcitabine (ddC) and nevirapine.
Blocking human immunodeficiency virus (HIV) entry, which begins with highly specific binding of the HIV envelope glycoprotein gpl20 to a CD4molecule on the surface of most susceptible cells1~3), is one of the most important targets of HIVtherapy4).
While screening for activities against gpl20-CD4
binding from microorganisms, we discovered the novel inhibitors, isochromophilones I and II, from the fungus, Penicillium multicolor5~n\ Here, we report additional two gpl20-CD4 binding inhibitors, chloropeptins I and II ( Fig. 1 ), produced by Streptomyces sp. isolated from a soil sample. This paper describes the taxonomy, fermentation, isolation, physico-chemical properties and biological activities of these compounds,a preliminary account of which was published in this journal8). The structure elucidation will be separately reported9).
Materials and Methods
Producing Organism and Taxonomy To examine the morphological and cultural properties, strain WK-3419was cultured as described by International Streptomyces Project10'11}. Morphology was observed under a light microscope (Olympus Vanox-S AH-2) and a scanning electron microscope (Hitachi S-430). The culture was examined after an incubation at JAN. 1997 27°C for 14 days. The color was judged by the Color Harmony Manual12). The physiological properties including carbon utilization were examined as described by Pridham and Gotlieb13). Diaminopimelic acid was analyzed as described by Becker et al.14\
Fermentation A loopful of mycelia from a dense slant culture of strain WK-3419was transferred into a large test tube (2 x 20cm) containing 10ml of a medium consisting of starch 2.4%, glucose 1.0%, peptone 0.3%, meat extract 0.3%, yeast extract 0.5% and CaCO3 0.4% (adjusted to pH 7.0 before sterilization).
The tube was incubated at 27°C on a reciprocal shaker at 300rpm for 3 days to give a first seed culture. This culture (2ml) was transferred into a 500-ml Erlenmeyer flask containing 100ml of the above medium, and was incubated at 27°Con a rotary shaker (200 rpm) for 4 days to give a second seed culture. This culture (600ml) was transferred into a 50-liter jar fermenter containing 30 liters of the above medium supplemented with allophane 0.5% (non-crystalline aluminosilicic clay from Asahi Chemical Co., Ltd.) and 4ml/liter of trace metal solution, containing 1.0g each of FeSO2 H2O, MnCl2-4H2O, ZnSO4-7H2O, CuSO4-5H2O and CoCl2 à" 2H2O per liter. Chloropeptin production was monitored by HPLCusing a CAPCELL PAK C18 column and acetonitrile-THF-0.1% phosphoric acid (37 : 8 : 55) as the developing solvent. Fermentation proceeded at 27°C for 7 days under aerobic conditions. 
Spectral Analysis
UVand visible spectra were recorded on a Shimadzu UV-160A spectrophotometer and IR spectra were recorded on a Jasco A-102 spectrophotometer. Mass and NMR spectra were obtained on JMS-SX102A and
Varian XL-400 spectrometers, respectively.
Gpl20-CD4 Binding Assay
Binding ofrecombinant sCD4 (rsCD4) to recombinant gpl20 (rgpl20) adsorbed on a 96-well plate was assayed by ELISA as described by Gilbert et al.15 ). To 96-well plates coated with rgpl20 (2.0 /ig/ml), rsCD4 (l.O^g/ml), bovine serum albumin (BSA, 5.0mg/ml) and sample solution were added, then incubated for 1 hour at room temperature. The plates were washed, then anti-CD4-mAB(8E7.H8) was added and incubated for 1 hour at room temperature. The plates were treated with mouse anti-IgG-HRP, then bound rsCD4 was assayed colorimetrically.
Anti-HIV Assay
The activity of a sample against HIV-1IIIB was determined on the basis of virus-induced cytopathogenicity in MT-4 cells as described by Nakashima et al}6). The cytotoxicity of the sample was evaluated in parallel with the antiviral activity and compared with the viability of mock-infected cells by the MTTmethod. In the assay, after HIV-1-infected cells were incubated with a test sample at 37°Cfor 5 days, the viable cells were counted by the MTTmethod.
Syncytium Formation Inhibition Assay This assay preceeded as described by Nakashima et al.16 ). In the assay, MOLT-4cells and HIV-1-infected MOLT-4 cells (MOLT-4/HIV-lIIIB) were mixed and incubated at 37°C for 20 hours. Thereafter, the cells were counted and the percent fusion inhibition was calculated. Cytotoxicity HeLa-S3 and CEMcells were anchorage-dependent and -independent, respectively. Cells were incubated in Eagle's minimumessential medium containing 10% fetal calf serum at 37°C in a 5% CO2 -95% atmosphere. To determine cytotoxicity, cells suspended in 200fA of the medium (3 x 104cells/ml) were plated in 96-well culture plates and incubated for 24 hours at 37°C. To each well was added a sample solution dissolved in dimethylsulfoxide (DMSO; final concentration, 1.25%).
After 72-hour incubation, the cell growth was measured colorimetrically by the tetrazolium salt (MTT) method.
Antimicrobial Activity Antimicrobial activity was assayed by the conventional paper disc method using the following media and 8 mm paper discs (50//I of sample was added to each disc). Bacteria were incubated in mediumcontaining peptone 0.5%, meat extract 0.5% and agar 1.0% (pH 7.0) at 37°C, fungi in medium containing glucose 1.0%, yeast extract 0.5% and agar 1.0% (pH 7.0) at 27°C, and mycoplasma in that containing PPLO Broth (Difco)
2.1%, glucose 0.1%, horse serum 15%, phenol red 10/ig/ml and agar 1.2% at 37°C.
Analysis of CompoundCombination Effect
The inhibition of HIV replication by chloropeptin I and AZT, ddl, ddC or nevirapine was examined by a checkerboard method. The antiviral activity in combination-treated HIV-infected MT-4 cells was determined for the protection against HIV-induced CPE provided by the MTTmethod, as described above. Vegetative mycelia grew abundantly on yeast extractmalt extract, oatmeal and other agar media, but did not fragment into coccoid forms or bacillary elements. The aerial mycelia grew abundantly on yeast extract -malt extract, inorganic salts -starch and other agar media. The spore chains were of the spirales type and each had over 20 spores per chain. The spores were ovoid in shape, 1.4x0.9mm in size and had a spiny surface (Fig. 2) .
Whirls, sclerotic granules, sporangia and flagellate spores were not observed. The cultural characteristics and the physiological properties are shown in Tables 1 and 2 However, chloropeptin I differed from complestatin in terms of optical rotation, UVspectrum and solubility in methanol, although their molecular formulae water, but not in hexane, chloroform and ethyl acetate.
However, their solubility in lower alcohols differed. Complestatin (chloropeptin II) is essentially in-soluble in methanol whereas chloropeptin I is soluble. The UV spectra of chloropeptin I and complestatin both under-went a bathochromic shift. Weconsidered from the data shown in Table 3 that chloropeptin I is also a peptide containing chlorinated phenol groups. The structure elucidation will be separately reported9).
Biological Activities Chloropeptin I and complestatin potently inhibited gpl20-CD4 binding (IC50: 1.3 and 2.0/im, respectively) Fig. 4 A shown in Table 5 , chloropeptin I and complestatin exhibited relatively low antimicrobial activities against some Gram-positive bacteria and a mycoplasma, and none against the other microorganisms tested, (Mycobacterium smegmatis ATCC607, Escherichia coli: NIHJ and NIHJ JC-2 (IFO-12734), Pseudomonas aeruginosa P-3, Xanthomonas orizae KB88, Bacteroides fragilis KB169, Candida albicans KF1 , Mucor racemosus KF223 Chloropeptin I (O) or complestatin (à") and rsCD4 (1.0^g/ml) at the indicated concentration were added to rgpl20-coated plates and then incubated for 60 minutes, at room temperature in the presence of 5.0mg/ml BSA. The Chloropeptin I administered intravenously to mice at a dose of lOOmg/kgdid not cause acute toxicity.
Combination of Chloropeptin I and AZT, ddl, ddC or Nevirapine in In Vitro Anti-HIV Assay Next, we investigated whether chloropeptin I showed synergistic or additive effects when it was used concomitantly with reverse transcriptase inhibitors. We first investigated the antiviral effect of chloropeptin I combined with AZTin acutely HIV-infected MT-4 cells, which was monitored by the protection against HIVinduced CPE. The calculated additivity surface was subtracted from the experimental surface and plotted in 3-D form (Fig. 6A ). These plots would reveal a horizontal plane at 0%if the interactions were purely additive. The combinations of chloropeptin I and AZTin the dose range tested were consistently more effective than the use of either compoundalone because the plots appeared above the plane with a height corresponding to the present above the calculated additivity. Whenwe tested Table 4 . Anti-HIV-1 activities of chloropeptin I, complestatin, dextran sulfate and AZT. 
